Sign In
Buy FLGT
$16.55
-3.66 (-18.11%)
At Close: Jul 31, 2026
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform
01:36pm, Tuesday, 23'rd Dec 2025
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
04:10pm, Monday, 22'nd Dec 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development
Financial Contrast: Patient Portal Technologies (OTCMKTS:PPRG) versus Fulgent Genetics (NASDAQ:FLGT)
02:10am, Sunday, 30'th Nov 2025
Fulgent Genetics (NASDAQ: FLGT - Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will c
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
09:04am, Tuesday, 11'th Nov 2025
Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer
Fulgent to Participate in Upcoming Conferences
04:05pm, Friday, 07'th Nov 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
02:56pm, Friday, 07'th Nov 2025
Fulgent Genetics, Inc. ( FLGT ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financi
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
09:20am, Friday, 07'th Nov 2025
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to earnings of $0.31 per share a yea
Fulgent Reports Third Quarter 2025 Financial Results
07:05am, Friday, 07'th Nov 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
06:00am, Monday, 20'th Oct 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a the
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
07:00am, Thursday, 16'th Oct 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Genetics: A Risky Bet or a Hidden Gem?
07:00pm, Thursday, 11'th Sep 2025
Explore the exciting world of Fulgent Genetics (FLGT 2.11%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into marke
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
01:58pm, Monday, 08'th Sep 2025
While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics a
Fulgent (FLGT) Q2 Revenue Jumps 16%
07:54am, Saturday, 02'nd Aug 2025
Fulgent (FLGT) Q2 Revenue Jumps 16%
Why Fulgent Genetics Stock Was Crushing It on Friday
04:26pm, Friday, 01'st Aug 2025
Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (FLGT 7.80%). The company's shares were soaring in late-session action, with a very healthy r
Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript
12:28pm, Friday, 01'st Aug 2025
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim -
